Dendreon Completes Submission of Biologics License Application to FDA for PROVENGE in Hormone Refractory Prostate Cancer
13th Nov 2006, 21:51 GMT
Dendreon Corp announced that the final portion of the Biologics License Application for PROVENGE has been electronically submitted to the US FDA, which completes its rolling submission that began in August 2006.
Dendreon Completes Submission of Biologics License Application to FDA for PROVENGE in Hormone Refractory Prostate Cancer related news:
- Dendreon Asks FDA to OK Prostate Drug — Government/ Industry Regulation News from StratCenter.com
- Dendreon seeks OK for Provenge — United Press International - Health Business
- Dendreon completes FDA filing for prostate-cancer drug — The Seattle Times: Horse racing
- Scientists Discover Way To Block Growth Of Prostate Cancer Cells — Health News from Medical News Today
- Aeterna prostate cancer drug shows promise — Pharmaceutical Business Review Latest News
- FDA Grants Priority Review for Soliris BLA for Treatment of Paroxysmal Nocturnal Hemoglobinuria — StratWire - Business of Healthcare NewsFeed
- ReGen Biologics Announces Results of FDA Appeal — Government/ Industry Regulation News from StratCenter.com
- Prostate-specific symptoms of prostate cancer in a German general population — Prostate Cancer and Prostatic Diseases
- Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: results from Early Prostate Cancer Trial 24 at a median 7 years' follow-up — Prostate Cancer and Prostatic Diseases
- 'Muscle' Protein Drives Prostate Cancer — Health News from Medical News Today
Latest news from Government/ Industry Regulation News from StratCenter.com:
- PLC Systems to Show RenalGuard at Medica 2006
- National Public Health Summit Targets Cervical Cancer Elimination
- MediPurpose Announces Exclusive Distribution Agreement for Sangofer Blood Separation Product
- Portrait PSR3 by Rhytec named in TIME Magazine's 2006 Skin Technology Story
- Pharsight Invited to Present on Model-Based Drug Development rd Annual Australian Health and Medical Research Congress
- Spectrum Pharmaceuticals Announces Presentation of Ozarelix Data at the Congress of the Societe Internationale d'Urologie
- Newly FDA Approved SmartLipo Laser Liposuction Available at the Intimate Rejuvenation and Innovative Surgery Center, Phoenix, AZ
- Sector Election Boosts Stem Cells
- AUDIO From Medialink and AARP: Voters' Call for Change Signals New Directions for Health Care
- Schering-Plough CEO Calls on New Congress to 'Do What Is Right' for the Patient, Calls for 'Scorecards' to Rate Managed Care Performance